9. A method of treating inflammatory bowel disease in a mammal, the method comprising administering a low dose pharmaceutical composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid or its pharmaceutically acceptable salt.
10. The method according to claim 9 wherein [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid or its pharmaceutically acceptable salt is in a range of 2.5mg to 60mg.
11. The method according to claim 9 wherein low dose pharmaceutical composition is effective in the dosage range of 2.5 mg to 60 mg per day.
12. The method according to claims 9-11, wherein low dose pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier selected from diluent, binder, disintegrant, pH adjusting agent and/or lubricant.
13. A pharmaceutical composition comprising [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid or its pharmaceutically acceptable salt, as herein described with reference to the examples accompanying the specification.